Cardiovascular imaging is essential for diagnosing heart failure with preserved ejection fraction, identifying distinct biological phenotypes such as myocardial fibrosis, and guiding risk stratification.
Heart failure with preserved ejection fraction (HFpEF) does not exist as a singular clinical or pathological entity but as a syndrome encompassing a wide range of clinical and biological phenotypes. There is an urgent need to progress from the unsuccessful 'one-size-fits-all' approach to more precise disease classification, in order to develop targeted therapies, personalise risk stratification and guide future research. In this regard, this review discusses the current and emerging roles of cardiovascular imaging for the diagnosis of HFpEF, for distilling HFpEF into distinct disease entities according to underlying pathobiology and for risk stratification.
Lewis et al. (Thu,) conducted a review in Heart failure with preserved ejection fraction (HFpEF). Cardiovascular imaging was evaluated. Cardiovascular imaging is essential for diagnosing heart failure with preserved ejection fraction, identifying distinct biological phenotypes such as myocardial fibrosis, and guiding risk stratification.